The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
JITC launched two new sections in 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy," and submit today!
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 10.252 in 2020. JITC’s Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 7% percent of all journals published in the categories of oncology and immunology.Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2019 citations accumulated for JITC manuscripts published in 2017 and 2018. Other valuable journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 50 percent discount on processing fees for all JITC articles submitted and accepted in 2020.
For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cells’ survival and function. During the last decade, immunotherapies targeting IRs such as programmed cell death receptor 1 (PD-1) and anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) have provided ample evidence of clinical benefits in many solid tumors. Beyond CTLA-4 and PD-1, multiple other IRs are also targeted with immune checkpoint blockade in the clinic. Specifically, T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a promising new target for cancer immunotherapy. TIGIT is upregulated by immune cells, including activated T cells, natural killer cells, and regulatory T cells. TIGIT binds to two ligands, CD155 (PVR) and CD112 (PVRL2, nectin-2), that are expressed by tumor cells and antigen-presenting cells in the tumor microenvironment. There is now ample evidence that the TIGIT pathway regulates T cell-mediated and natural killer cell-mediated tumor recognition in vivo and in vitro. Dual PD-1/TIGIT blockade potently increases tumor antigen-specific CD8+ T cell expansion and function in vitro and promotes tumor rejection in mouse tumor models. These findings support development of ongoing clinical trials with dual PD-1/TIGIT blockade in patients with cancer.
Adoptive cell therapy with chimeric antigen receptor T cells (CAR-T) has become a standard treatment for patients with certain aggressive B cell malignancies and holds promise to improve the care of patients suffering from numerous other cancers in the future. However, the high manufacturing cost of CAR-T cell therapies poses a major barrier to their broader clinical application. Among the key cost drivers of CAR-T production are single-use reagents for T cell activation and clinical-grade viral vector. The presence of variable amounts of contaminating monocytes in the starting material poses an additional challenge to CAR-T manufacturing, since they can impede T cell stimulation and transduction, resulting in manufacturing failure.
Dear colleagues: I would like to share the following press release [ https://sunnybrook.ca/research/media/item.asp?c=2&i=2222], concerning our recent JCI Insight paper [DOI: 10.1172/jci.insight.141293; see attached file] that is relevant to adoptive ...
9th Annual Lung Cancer Symposium - Virtual Meeting March 4-5, 2021 https://cme.jefferson.edu/content/lung2021
The 9th Annual Lung Cancer Symposium will offer attendees the opportunity for a comprehensive update in lung cancer while interacting ...
Thank you for the invite I will like to attend. Adoke ------------------------------ Kasimu Adoke MBBS Consultant Federal Medical Center Birnin Kebbi Birnin Kebbi ------------------------------
Hello SITC Community Member, Trust you are well. We warmly welcome you and your colleagues for Orphan Drugs and Rare Diseases 2nd Edition Digital Event on 3rd & 4th December 2020 (Webinar). PFA Agenda for your reference .
I am writing to ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com